LipoRed - Munich Biotech
Alternative Names: LipoRedLatest Information Update: 15 Sep 2015
Price :
$50 *
At a glance
- Originator Munich Biotech (CEASED)
- Class
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 13 Feb 2004 Phase-I/II clinical trials in Solid tumour diagnosis in Germany (IV)